Cytosorbents Corp (CTSO)

Cytosorbents Stock Analysis & Ratings

CTSO Stock Chart & Stats

Day’s Range$2.11 - $2.27
52-Week Range$1.78 - $9.80
Previous Close$2.13
Average Volume (3M)213.32K
Market Cap$93.22M
P/E Ratio-3.2
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-0.68



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cytosorbents’s price range in the past 12 months?
Cytosorbents lowest stock price was $1.78 and its highest was $9.80 in the past 12 months.
    What is Cytosorbents’s market cap?
    Cytosorbents’s market cap is $93.22M.
      What is Cytosorbents’s price target?
      The average price target for Cytosorbents is $9.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $16.00 ,the lowest forecast is $5.00. The average price target represents 320.56% Increase from the current price of $2.14.
        What do analysts say about Cytosorbents?
        Cytosorbents’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Cytosorbents’s upcoming earnings report date?
          Cytosorbents’s upcoming earnings report date is Aug 09, 2022 which is in 83 days.
            How were Cytosorbents’s earnings last quarter?
            Cytosorbents released its earnings results on May 03, 2022. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.144 by -$0.066.
              Is Cytosorbents overvalued?
              According to Wall Street analysts Cytosorbents’s price is currently Undervalued.
                Does Cytosorbents pay dividends?
                Cytosorbents does not currently pay dividends.
                What is Cytosorbents’s EPS estimate?
                Cytosorbents’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Cytosorbents have?
                Cytosorbents has 43,160,000 shares outstanding.
                  What happened to Cytosorbents’s price movement after its last earnings report?
                  Cytosorbents reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.144. Following the earnings report the stock price went down -2.752%.
                    Which hedge fund is a major shareholder of Cytosorbents?
                    Among the largest hedge funds holding Cytosorbents’s share is Royce & Associates LLC. It holds Cytosorbents’s shares valued at 1M.


                      Cytosorbents Stock Analysis

                      The Cytosorbents stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cytosorbents Corp

                      CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

                      Similar Stocks
                      Price & Change
                      Baxter International
                      Aethlon Medical
                      Fresenius Medical Care

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis